Cambridge Healthtech Institute’s 2nd Annual

Cancer Biotherapeutics
Immune Modulation, Bi-Specifics, ADCs, Synergistic Mechanisms and Unique Approaches
6-7 November 2014


Research in 2014 for this event reveals a huge increase in the interest in immunotherapy and continued interest in bi-and multi-specific products, combination approaches, and antibody drug conjugates. This conference track will present advances in all of these areas from discovery to development, and provide details on innovative modes of action, and on application and efficacy.  Safety considerations for these new approaches will also be covered.

Preliminary Agenda


TARGETING THE IMMUNE RESPONSE 

Safety Challenges and Risk Mitigation Strategies to Develop Immune Activating Biologics

Rakesh Dixit, Ph.D., Vice President, R&D, Safety Assessment, Medimmune, Inc.

ImmTACs: TCR-Based Bispecific Reagents for Targeted Cancer Therapy

Dr Annelise Vuidepot, Ph.D., Head, Protein Science, Immunocore Ltd.

Targeting Cancer with BiTE Molecules

Holger Wesche, Ph.D., Scientific Director, Oncology, Amgen, Inc.

Targeting Immune Checkpoints in Cancer: Novel Mechanistic Insights on the Role of Fc Receptors and the Tumour Microenvironment

Sergio A. Quezada, Ph.D., Professorial Research Fellow, Research Haematology, University College London Cancer Institute

Discovery and Development of Fusion Proteins and Antibodies Modulating the Immune Response in Malignancy and Enhancing Overall Effector Function

Sol Langerman, Ph.D., CSO, R&D, Amplimmune


BISPECIFIC ANTIBODIES FOR CANCER 

Targeting of Solid Tumors with Bispecifics and Bispecific ADCs: Inducing Novel Biologics and Drug-Like Properties

David Poon, Director External R&D and Alliances, Zymeworks, Inc.

Preclinical Developments with a Fully-Human Bispecific Antibody Platform

Eric Smith, Ph.D., Associate Director, Bispecific Antibodies, Regeneron Pharmaceuticals, Inc.


DEVELOPMENTS WITH ADCs 

Discovery of Novel Linkers, Payloads and Antibody-Drug Conjugates for the Treatment of Cancer

Edmund I. Graziani, Ph.D., Associate Research Fellow, Oncology Medicinal Chemistry, Pfizer, Inc.

Producing Homogeneous ADCs with Single or Combination Warheads

Aaron Sato, Ph.D., Vice President, Research, Sutro Biopharma, Inc.

Targeted Delivery of Cytotoxic Agents for Cancer Treatment

Gonçalo Bernardes, Ph.D., Royal Society, University Research Fellow, Chemistry, University of Cambridge


SYNERGISTIC MECHANISMS 

IgA as a Novel Antibody Isotype for the Treatment of Cancer: Potential Synergy with IgG Antibodies

Jeanette Leusen, Ph.D., Associate Professor, Translational Immunology, University Medical Center, Utrecht


COMPLEMENT ACTIVATION, AND ENHANCED ADCC 

The Mechanism of Complement Activation by IgG Antibodies

Janine Schuurman, Ph.D., VP, Research, Genmab

ARGX-111, a Defucosylated Antagonistic Anti-MET Antibody that Displays Potent Anti-Tumor Activity through Enhanced ADCC

Natalie de Jonge, Ph.D., Senior Scientist, arGEN-X


CLINICAL DEVELOPMENTS 

Clinical Development of Tanibirumab and its Next Generation of Bispecific Antibody

Jin-San Yoo, Ph.D., CEO and President, PharmAbcine, Inc.